Mystery around death of 1-year-old ‘ice prince' from medieval Germany now solved
Dressed in fine silk, linen and leather, archaeologists knew right away the child must have been a member of a high-status, regionally important family, according to a May 22 news release from the Bavarian State Office for Monument Preservation.
To preserve the contents of the child's grave, discovered about 56 miles west of Munich in Tussenhausen, experts flash-froze the burial chamber. This allowed them to lift it out of the ground as one whole piece — a technique specially developed by the Bavarian State Office for Monument Preservation, according to the release.
Scientists determined the blond, blue-eyed child, who came to be known as the 'Ice Prince of Mattsies' thanks to the preservation technique used on his grave, lived some time between 670 and 680 AD.
It was determined the child died at the age of 1 1/2 from a chronic infection stemming from a middle ear infection, according to the release. This was a common fate for children in the Middle Ages, experts said.
Most children, however, were not buried with such riches.
The Ice Prince of Mattsies was buried on a Roman estate in a building that was adapted to be a burial and memorial site, according to the release. The burial chamber was made entirely of stone and carved by skilled stonemasons, experts said.
Inside, the child was laid to rest on a hide. He was dressed in a long-sleeved shirt made of fine linen and silk, which experts said could only be obtained through contact with the Byzantine Empire and was a status symbol.
He wore silver bracelets on his arms and silver spurs on his shoes. He also wore a sword with a leather scabbard ornately decorated with gold, officials said.
Objects at the foot of his burial chamber indicated the family's high status, including a bronze basin that contained a comb, a wooden bowl, a drinking cup with silver fittings, and the remains of hazelnuts, apples, and a pear, according to the release.
Experts said the burial room had been re-roofed twice, including that it was used as a place of remembrance for many years, per the release.
Google Translate was used to translate the news release from the Bavarian State Office for Monument Preservation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly-owned Alzheimer's disease franchise now includes clinical-stage anti-tau antibody VY7523 as well as gene therapies targeting tau, amyloid, and APOE - LEXINGTON, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today continued the expansion of its Alzheimer's disease (AD) franchise with the introduction of a wholly-owned program that modulates the expression of apolipoprotein E (APOE), the strongest genetic risk factor for AD.i The program uses a proprietary intravenous (IV)-delivered, blood-brain barrier (BBB)-penetrant TRACER capsid to deliver a bifunctional payload that is designed to decrease expression of APOE in carriers of the variant APOE4, while delivering the variant APOE2. APOE4 has been strongly linked with a higher risk of developing AD, with almost all APOE4 homozygotes exhibiting AD pathologyi, while APOE2 has been associated with a lower risk of developing AD. In preclinical studies, a single IV injection of a TRACER capsid carrying the single bifunctional vector resulted in significant reductions of endogenous APOE4 in key AD-relevant brain regions of APOE4 knock-in mice, while significantly increasing expression of the APOE2 isoform to maintain overall APOE levels. Voyager anticipates presenting early data on this program at an upcoming scientific meeting in 2025. 'The Voyager team is leveraging our deep expertise in Alzheimer's disease biology and drug development to advance multiple programs against what we believe to be the three most-promising targets: tau, amyloid, and APOE,' said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. 'We believe each of these approaches will have an important role to play in the treatment of Alzheimer's disease, particularly as the field begins to understand how best to sequence and combine treatments to improve outcomes for patients. We look forward to near-term data on some of these targets expected from third parties, which we expect will continue to inform our Alzheimer's disease franchise and approach.' Voyager's AD franchise is now comprised of four wholly-owned assets: VY7523, a pathologic-specific anti-tau antibody, which is being evaluated in a multiple ascending dose (MAD) clinical trial in AD patients, with initial tau positron emission tomography (PET) data expected in the second half of 2026. VY1706, an IV-delivered tau silencing gene therapy that has shown up to 73% knockdown of tau mRNA in non-human primates following a single IV dose and is advancing towards IND in 2026. A vectorized anti-Aβ antibody gene therapy, which demonstrated over 15-fold greater brain-to-plasma ratio after a single IV dose compared to a passively administered antibody over 4 weeks in a murine model, as presented at the American Society of Gene & Cell Therapy's (ASGCT) 28th Annual Meeting. The APOE gene therapy program, which is designed to knock down APOE in APOE4 carriers while delivering APOE2 and maintaining total APOE levels. About the TRACER™ Capsid Discovery Platform Voyager's TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of novel AAV capsids to enable gene therapy. Voyager has leveraged TRACER to create multiple families of novel capsids that, following intravenous delivery in preclinical studies, harness the extensive vasculature of the central nervous system (CNS) to cross the blood-brain barrier and transduce a broad range of CNS regions and cell types. In cross-species preclinical studies (rodents and multiple non-human primate species), intravenous delivery of TRACER-generated capsids resulted in widespread payload expression across the CNS at relatively low doses, enabling selection of multiple development candidates in Voyager's wholly-owned and partnered gene therapy programs for neurologic diseases. About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as 'will,' 'expect,' 'believe,' 'anticipate,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding Voyager's continued expansion of its AD franchise by advancing multiple programs against tau, amyloid and APOE to treat AD and the potential to sequence and combine such treatments to improve therapeutic outcomes for patients; Voyager's ability to advance its AAV-based gene therapy programs and tau antibody program, including expectations for Voyager's achievement of preclinical and clinical development milestones for its potential development candidates such as the IND filings, the initiation of clinical trials, clinical trial enrollment, and the generation of clinical data; Voyager's ability to advance preclinical programs (i) against ApoE using a single IV-injected TRACER capsid to deliver a bifunctional payload to reduce endogenous ApoE4, as well as (ii) against amyloid by its vectorized anti-Ab antibody gene therapy. Voyager's plans to present scientific data at future conferences; the commercial potential for VY7523 and VY1706; the importance of tau as a target for the treatment of AD; and the potential for third-party clinical data to inform Voyager's clinical development plans are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager's management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain and subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the expectations and decisions of regulatory authorities; the timing, initiation, conduct and outcomes of Voyager's preclinical and clinical studies; the availability of data from clinical trials; the availability or commercial potential of product candidates under collaborations; the success of Voyager's product candidates; the willingness and ability of Voyager's collaboration partners to meet obligations under collaboration agreements with Voyager; the continued development of Voyager's technology platforms, including Voyager's TRACER platform and its non-viral discovery platform; Voyager's scientific approach and program development progress, and the restricted supply and increased costs of critical research components; the development by third parties of capsid identification platforms that may be competitive to Voyager's TRACER capsid discovery platform; Voyager's ability to create and protect intellectual property rights associated with the TRACER capsid and non-viral discovery platform, the ligands identified by the platform, and development and clinical candidates for Voyager's pipeline programs; the possibility or the timing of Voyager's receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager's existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the success of programs controlled by third-party collaboration partners in which Voyager retains a financial interest; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of Voyager's cash resources to fund its operations and pursue its corporate objectives. These statements are also subject to a number of material risks and uncertainties that are described in Voyager's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Contacts Trista Morrison, tmorrison@ Investors: Sarah McCabe, smccabe@ Media: Adam Silverstein, adam@ ____________________________________i Fortea, J., Pegueroles, J., Alcolea, D. et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease. Nat Med 30, 1284–1291 (2024). in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
2 days ago
- New York Post
Mysterious 1,600-year-old settlement emerges from soil with rare Roman military finds
Archaeologists recently uncovered a mysterious Roman-era settlement site in Germany, complete with building remains and hundreds of artifacts dating back nearly two millennia. The Schafbreite site, located within the western German town of Delbrück, has been settled since the first century A.D. The site was recently excavated by the Regional Association of Westphalia-Lippe (LWL). Advertisement In a June 13 statement, the LWL announced the results of its excavation, revealing a trove of discoveries that mostly date back to the fourth and fifth centuries A.D. Officials identified hundreds of ancient features at the site, including numerous holes in the ground that were likely from ancient wooden posts. After months of careful digging, archaeologists also found two 'clearly identifiable' buildings, along with two pit houses, two wells and a cremation grave — along with several hundred artifacts. 5 Archaeologists excavating a Roman-era settlement in Germany. EggensteinExca/S. Knippschild via LWL Advertisement 5 Ancient Roman glass bead. LWL Archaeology for Westphalia/A. Madziala 'Seven hundred and fifty individual finds were recovered from the ancient cultural layer preserved under a thick ash soil, 600 of which were metal,' said the LWL's statement, translated from German to English. Archaeologists also explained that the site 'must have been settled at different times, making it a multi-period settlement site.' 'The finds from various periods also show the inhabitants had access to Roman material culture.' Advertisement 'The finds from various periods also show that the inhabitants had access to Roman material culture,' the press release said. The statement added, 'The new excavations have expanded the picture of this site, as a burial has now been confirmed: The isolated cremation grave contained remains from the pyre, such as charcoal, cremated remains and parts of burned grave goods.' 5 Excavated Roman-era well shaft in Germany. EggensteinExca/S. Knippschild via LWL 5 Carved wooden beam unearthed at a Roman-era settlement in Delbrück-Bentfeld, Germany. LWL Archaeology for Westphalia/A. Madziala Advertisement 'Experts date this buckle to the 4th or 5th century based on its shape. It further confirms the settlers' contact with the Roman cultural sphere, as it belonged to the Roman military belt,' officials said in a statement. Historians were unable to identify the mysterious burial. The LWL speculated that the deceased person may have been a Germanic mercenary in the Roman military. '[It's] a special find, as it is the first burial in East Westphalia where parts of a Roman military belt have been detected, previously only known from surface finds in other regions,' officials said. Other discoveries at the site included a cattle trough, a construction pit with ceramics and a three-foot-wide well that was made from tree trunks. 'The organic preservation was so good that we recovered not only wood but also a leather fragment and even an insect wing,' excavation manager Sven Knippschild noted. He added, 'Completely extraordinary and unique for the Migration Period in Westphalia was the discovery of a beam piece with various tool marks on the last day of excavation.' '[It] was certainly once part of a house and was later recycled for the well construction.' Sven Spiong, a lead archaeologist at LWL, said the site offers a glimpse into what life was like during the Migration Period. Advertisement 5 Eyelet from a Roman military belt. EggensteinExca/S. Knippschild via LWL The era, also known as the Barbarian Invasions, was a time of significant upheaval and change in Europe, lasting from roughly 300 to 600 A.D. 'Sites like these help us better understand how the people of the region lived and worked during the arrival of the Romans and in the following centuries.' 'Sites like these help us better understand how the people of the region lived and worked during the arrival of the Romans and in the following centuries, what interregional contacts and connections they had, and how the settlement structure changed during the Migration Period,' Spiong said. Advertisement Even though the excavation has wrapped up, the recent discoveries are just the beginning of researchers' study of the archaeological site. Experts plan to analyze the wood and charcoal found at the site to help date the site more precisely. Archaeologists will also look at some soil from the well to learn more about what the area around Bentfeld was like over 1,600 years ago. 'This [study] may reveal changes in vegetation, landscape, and settlement between the time around the birth of Christ and around 400 A.D.,' LWL archaeologist Julia Hallenkamp-Lumpe noted.
New York Post
2 days ago
- New York Post
Breast cancer survivors were less likely to get Alzheimer's if they underwent this treatment: study
A breast cancer battle might come with an unexpected silver lining. New research suggests survivors may have a lower risk of developing Alzheimer's dementia (AD) compared to women without a history of the disease. One treatment, in particular, appears to offer the most protection — but there's a major catch. 4 In the United States, an estimated 6.7 million people have Alzheimer's disease. pikselstock – For the study, Korean scientists analyzed health records of over 70,000 women treated for breast cancer between 2010 and 2016, comparing them with a control group of about 180,000 healthy participants. Over an average follow-up of 7.3 years, 1,229 breast cancer survivors were diagnosed with Alzheimer's. Compared to the control group, these survivors had an 8% lower risk of developing the disease. The reduced risk was strongest among women aged 65 and older who received their breast cancer diagnosis later in life. Radiation therapy, the most common treatment among these patients, uses high-energy rays to kill cancer cells and shrink tumors. It is often administered after surgery to eliminate any remaining cancer cells and reduce the risk of recurrence. The study found that the treatment also offered the greatest protective effect against Alzheimer's, reducing the risk by 23%. 4 Radiation is used to kill cancer cells and reduce the risk of recurrence after surgery. ihorvsn – The finding surprised researchers, given widespread fears about cognitive decline in breast cancer patients after treatment, often referred to as 'chemo brain.' 'Concerns about chemo brain and the long-term adverse effects of breast cancer treatment on cognition are common, but our findings suggest this treatment does not directly lead to [Alzheimer's disease],' the study authors wrote. They highlighted earlier studies suggesting that certain breast cancer therapies may help reduce the buildup of amyloid-beta and tau proteins — key markers of Alzheimer's disease. The team also found no significant link between other breast cancer treatments, such as chemotherapy or hormone therapy, and Alzheimer's risk. However, these findings contradict other studies that have reported a possible increased risk of Alzheimer's among some cancer survivors, especially older women. 4 The potential protective benefits of breast cancer treatments may diminish over time. Monkey Business – Notably, the researchers found that the protective benefit of breast cancer treatment didn't extend beyond five years. 'Based on these findings, we hypothesize that the risk of AD could be lowered shortly after cancer treatment but may equalize as the survival period increases,' the study authors wrote. They also acknowledged several limitations. Data on patients' breast cancer stage and radiation doses were unavailable, and some Alzheimer's diagnoses may have been missed. Since the study focused on patients with 'operable' breast cancer, its findings may not apply to elderly patients, those with serious comorbidities or people with advanced-stage disease. 4 The risk of Alzheimer's disease increases with age. Peakstock – And with a maximum follow-up period of 11 years, the scientists were unable to assess the long-term risk of Alzheimer's in breast cancer survivors. 'Additional studies with longer observation periods are needed to better understand the relationship between [Alzheimer's] risk and breast cancer survival duration,' the authors recommended. Breast cancer is one of the most common cancers among US women, with one in eight expected to develop the disease in their lifetime, according to the American Cancer Society. Alzheimer's also poses a growing public health challenge that disproportionately affects women, who account for nearly two-thirds of cases, per the Alzheimer's Association. The number of Americans diagnosed every year is projected to double by 2060, impacting 14 million adults. While there is currently no cure for Alzheimer's, medications and therapies are available that can help manage symptoms and may slow the progression of the memory-robbing disease — especially when it's detected early. 'Understanding the potential protective association of breast cancer on AD can enhance surveillance strategies for AD among these survivors,' the researchers wrote.
